Beyond the Copilot: Why Drug Development Demands Purpose-Built AI

The pharmaceutical industry is at a crossroads. While generic AI platforms can draft text, they often lack the structural rigor, regulatory compliance, and domain-specific intelligence required for end-to-end drug development. Join us for a deep dive into why "vertical" AI—engineered specifically for the high-stakes, highly regulated world of pharma—is the only way forward. What We’ll Explore The Compliance Gap: Why "bolted-on" compliance isn't enough for 21 CFR Part 11 and GxP requirements.Beyond "Good Enough": How purpose-built AI validates outputs against ICH and FDA acceptance criteria, moving past the risks of "AI-generated confidence".The Data Hierarchy Problem: Why understanding the relationship between parent protocols and regulatory commitments is the key to quality.Institutional Memory: The transformative power of AI agents that "remember" past FDA deficiency letters and regulatory feedback to sharpen submission strategies. Featured Panelists John Walter | The Industrial ArchitectJohn brings 20+ years of frontline experience in global drug manufacturing and development. Having navigated the "Administrative Tax" firsthand at Genentech and Thermo Fisher, he will detail how agentic infrastructure is the only viable path to reversing Eroom’s Law. He will lead the interrogation into why horizontal models fail to meet the rigorous GxP and 21 CFR standards required for production-grade life sciences. Austin Walsh (General Manager of Healthcare at Microsoft)A veteran of digital transformation who has scaled AI across the world’s largest healthcare and life sciences organizations.. Dr. Angela Jimenez (OpenAI Forum & NIH Veteran)Physician-Investor & Founder of Leon Precision Capital. Bringing a triple-threat perspective of clinical validity, investment viability, and federal regulatory experience from the NIH The conversation moves from the briefing room to the Empress Room at the Michelin-starred Investor Invite Only Dinner. Over a curated modern Cantonese prix fixe menu, an intimate group of VCs, LPs, and Family Offices will finalize the evening with a "Decision Table" discussions. VIP Dinner & Keynote: This private session features our keynote with Daniel Idźkowski, followed by an intimate "Decision Table" discussion on long-term capital stewardship and the future of deep-tech allocation. Drawing from his experience managing $1B+ in healthcare and deep-tech capital, Daniel share the impact of Biotech and AgeTech, positioning Family Offices as the sophisticated alternative to traditional VC. Panel Discussion: 3:00 - 5:30 PM PDTVIP Dinner & Keynote: 6:00 PM Target Audience: Institutional LPs, Family Offices, and Strategic VCs. Meet our Sponsors: ​ ​Sanai is a AI-mediated SaaS platform specifically targeting life-science operations and development. Accelerate time to market and make scaling easier by automating the most arduous tasks of data retrieval, review and verification. ​ ​Kranz Consulting is a leading accounting and financial solutions firm dedicated to helping start-ups and venture-backed companies scale with confidence. The firm believes every business, at every stage of growth, has a unique story to tell and works to ensure companies reach their full potential through expert financial guidance and strategic support. Kranz Consulting partners with founders and leadership teams to provide the tools, insights, and structure needed to grow efficiently and succeed in today’s competitive market. Meet our Co-Host ​​​​​​​​​​Berkeley Pharma Tech Foundation is a nonprofit committed to expanding biotech understanding and improving access to the industry through education, mentorship, and networking. We host roundtables, speaker panels, and community events to connect aspiring scientists and entrepreneurs with industry leaders. Our goals: launch a funded research program within two years and build a state-of-the-art lab in the Bay Area within five. Follow us on LinkedIn or reach out to Vanloan Nguyen to get involved!